Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference DOI Creative Commons
Dominik Linz, Jason G. Andrade, Elena Arbelo

et al.

EP Europace, Journal Year: 2024, Volume and Issue: 26(4)

Published: March 22, 2024

Abstract Aims Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated risk AF-related complications. The aim this document to summarize key outcomes 9th AFNET/EHRA Consensus Conference Atrial Fibrillation NETwork (AFNET) European Heart Rhythm Association (EHRA). Methods results Eighty-three international experts met Münster for 2 days September 2023. Key findings are as follows: (i) Active should be part default initial treatment all suitable AF. (ii) Patients device-detected AF have stroke. Anticoagulation prevents some strokes also increases major but non-lethal bleeding. (iii) More research needed improve stroke prediction AF, especially those burden. Biomolecules, genetics, imaging can this. (iv) presence trigger systematic workup comprehensive concomitant cardiovascular conditions. (v) Machine learning algorithms been used detection or likely development Cooperation between clinicians scientists leverage potential science applications Conclusions lower other events than high Combining control, anticoagulation, rate therapy conditions lives

Language: Английский

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease DOI Creative Commons
Paul E. Stevens, Sofia B. Ahmed, Juan Jesús Carrero

et al.

Kidney International, Journal Year: 2024, Volume and Issue: 105(4), P. S117 - S314

Published: March 13, 2024

This article is published as part of a supplement sponsored by Kidney Disease: Improving Global Outcomes (KDIGO). The opinions or views expressed in this are those the authors and do not necessarily reflect recommendations International Society Nephrology Elsevier. Dosages, indications, methods use for products that referred to may their clinical experience be derived from professional literature other sources.

Language: Английский

Citations

1936
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial DOI Creative Commons
Alexandre Mebazaa, Beth A. Davison,

Ovidiu Chioncel

et al.

The Lancet, Journal Year: 2022, Volume and Issue: 400(10367), P. 1938 - 1952

Published: Nov. 7, 2022

Language: Английский

Citations

592
Myocarditis DOI
Cristina Basso

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 387(16), P. 1488 - 1500

Published: Oct. 19, 2022

Myocarditis has increased with Covid-19 and vaccines. Precise diagnosis relies on endomyocardial biopsy, but MRI myocardial markers may be used. Treatment depends the cause degree of functional compromise.

Language: Английский

Citations

118
Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases DOI Creative Commons
Bettina Heidecker, Noa Dagan, Ran D. Balicer

et al.

European Journal of Heart Failure, Journal Year: 2022, Volume and Issue: 24(11), P. 2000 - 2018

Published: Sept. 6, 2022

Over 10 million doses of COVID-19 vaccines based on RNA technology, viral vectors, recombinant protein, and inactivated virus have been administered worldwide. Although generally very safe, post-vaccine myocarditis can result from adaptive humoral cellular, cardiac-specific inflammation within days weeks vaccination. Rates vaccine-associated vary by age sex with the highest rates in males between 12 39 years. The clinical course is mild rare cases left ventricular dysfunction, heart failure arrhythmias. Mild are likely underdiagnosed as cardiac magnetic resonance imaging (CMR) not commonly performed even suspected at all asymptomatic mildly symptomatic patients. Hospitalization patients electrocardiographic changes increased plasma troponin levels considered necessary acute phase to monitor for arrhythmias potential decline function. In addition evaluation symptoms, elevated levels, CMR best non-invasive diagnostic tool endomyocardial biopsy being restricted severe and/or management beyond guideline-directed treatment includes non-specific measures control pain. Anti-inflammatory drugs such non-steroidal anti-inflammatory drugs, corticosteroids used more cases, only anecdotal evidence their effectiveness. groups studied, overall risks SARS-CoV-2 infection-related hospitalization death hugely greater than myocarditis. This consensus statement serves a practical resource physicians practice, understand, diagnose, manage affected Furthermore, it intended stimulate research this area.

Language: Английский

Citations

109
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction DOI
Daniela Tomasoni, Gregg C. Fonarow, Marianna Adamo

et al.

European Journal of Heart Failure, Journal Year: 2021, Volume and Issue: 24(3), P. 431 - 441

Published: Dec. 11, 2021

Language: Английский

Citations

108
Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions DOI Creative Commons
Jun Ma, Yanan Li, Xiangyu Yang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: April 20, 2023

Abstract Hypertension is a global public health issue and the leading cause of premature death in humans. Despite more than century research, hypertension remains difficult to cure due its complex mechanisms involving multiple interactive factors our limited understanding it. condition that named after clinical features. Vascular function factor affects blood pressure directly, it main strategy for clinically controlling BP regulate constriction/relaxation vessels. elasticity, caliber, reactivity are all characteristic indicators reflecting vascular function. Blood vessels composed three distinct layers, out which endothelial cells intima smooth muscle media performers The alterations signaling pathways these key molecular underlying dysfunction development. In this manuscript, we will comprehensively review involved regulation progression, including calcium pathway, NO-NOsGC-cGMP various remodeling some important upstream such as renin-angiotensin-aldosterone system, oxidative stress-related immunity/inflammation etc. Meanwhile, also summarize treatment methods targets discuss possibility being applied work.

Language: Английский

Citations

108
Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis DOI Creative Commons
Jukka Lehtonen, Valtteri Uusitalo, Pauli Pöyhönen

et al.

European Heart Journal, Journal Year: 2023, Volume and Issue: 44(17), P. 1495 - 1510

Published: March 16, 2023

Cardiac sarcoidosis (CS) results from epithelioid cell granulomas infiltrating the myocardium and predisposing to conduction disturbances, ventricular tachyarrhythmias, heart failure. Manifest CS, however, constitutes only top of an iceberg as advanced imaging uncovers cardiac involvement 4 5 times more commonly than what is clinically detectable. Definite diagnosis CS requires myocardial biopsy histopathology, but a sufficient diagnostic likelihood can be achieved by combining extracardiac histology with clinical manifestations findings on imaging. appear first or organ manifestation pre-existing disease. Due lack controlled trials, care based observational evidence low quality. Currently, treatment involves corticosteroid-based, tiered immunosuppression control inflammation medical device-based therapy for symptomatic atrioventricular block, Recent outcome data indicate 90% 96% 5-year survival in manifest 10-year figures ranging 80% 90%. Major progress awaits key its molecular-genetic pathogenesis large-scale trials.

Language: Английский

Citations

106
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology DOI Open Access
Marco Metra, Daniela Tomasoni, Marianna Adamo

et al.

European Journal of Heart Failure, Journal Year: 2023, Volume and Issue: 25(6), P. 776 - 791

Published: April 27, 2023

Language: Английский

Citations

101
Ischemic Cardiomyopathy and Heart Failure After Acute Myocardial Infarction DOI Creative Commons
Marco Giuseppe Del Buono, Francesco Moroni, Rocco Antonio Montone

et al.

Current Cardiology Reports, Journal Year: 2022, Volume and Issue: 24(10), P. 1505 - 1515

Published: Aug. 16, 2022

Ischemic cardiomyopathy refers to systolic left ventricular dysfunction in the setting of obstructive coronary artery disease and represents most common cause heart failure worldwide. It is often combination an irreversible loss viable mass following acute myocardial infarction (AMI) with a dysfunctional, but still viable, myocardium context chronically reduced blood flow reserve. Medical treatments aiming at modulating neurohumoral response restoring ischemic cardiomyocytes were shown dramatically abate occurrence adverse remodeling cardiomyopathy.

Language: Английский

Citations

97
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF DOI Creative Commons
Kieran F. Docherty, Paul Welsh, Subodh Verma

et al.

Circulation, Journal Year: 2022, Volume and Issue: 146(13), P. 980 - 994

Published: Sept. 26, 2022

Background: Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence consequences of iron DAPA-HF trial (Dapagliflozin Prevention Adverse-Outcomes Heart Failure) effect dapagliflozin on markers metabolism. also analyzed outcomes, according to status at baseline. Methods: was defined as a ferritin level <100 ng/mL or transferrin saturation <20% 100 299 ng/mL. Additional biomarkers metabolism, including soluble receptor, erythropoietin, hepcidin were measured baseline 12 months after randomization. The primary outcome composite worsening (hospitalization urgent visit requiring intravenous therapy) cardiovascular death. Results: Of 4744 patients randomized DAPA-HF, 3009 had measurements available baseline, 1314 these participants (43.7%) deficient. rate higher (16.6 per person-years) compared those without (10.4 person-years; P <0.0001). consistent iron-deficient iron-replete (hazard ratio, 0.74 [95% CI, 0.58–0.92] versus 0.81 0.63–1.03]; -interaction=0.59). Similar findings observed for death, hospitalization, all-cause mortality. Transferrin saturation, ferritin, reduced total iron-binding capacity receptor increased placebo. Conclusions: Dapagliflozin appeared increase use but improved irrespective Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03036124.

Language: Английский

Citations

94